Researchers tested the addition of a pemetrexed-carboplatin chemotherapy regimen to gefitinib for patients with EGFR-mutant advanced non–small-cell lung cancer.
A retrospective study finds that use of checkpoint inhibitors is associated with similar survival outcomes among patients with advanced non–small-cell lung cancer, regardless of a history of autoimmune disorders.
The RELAY trial compared the combination of ramucirumab plus erlotinib vs erlotinib alone in patients with metastatic non–small-cell lung cancer.
The updated survival results from the COLUMBUS trial represent a promising new treatment option for patients with BRAF V600–mutant melanoma.
COMBI-i tested the anti–PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in previously untreated patients with advanced BRAF V600–mutant melanoma.
Researchers tested treatment with bone-protecting agents in men with metastatic castration-resistant prostate cancer treated with enzalutamide or radium-223.
A large international study looked at whether pregnancy is safe after breast cancer for women who have a BRCA mutation.
The survival benefit observed with gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia in the ADMIRAL trial was maintained regardless of the presence of several common co-mutations.
Investigators are now enrolling for a phase III trial testing the experimental immunotherapy tilsotolimod plus ipilimumab in patients with advanced melanoma who have progressed on anti–PD-1 therapy.
Investigators are now enrolling patients for a phase III trial, KEYNOTE-716, to assess the efficacy and safety of adjuvant pembrolizumab in adult and pediatric patients with surgically resected high-risk stage II melanoma.